╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Female subject is pregnant                         │ 15. Female subject is pregnant or plan to become   │
│                                                    │ pregnant                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have maximum age of 75 Years                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject needs mechanical ventilation               │ 10. Subject needs mechanical ventilation;          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients on standard treatment of chronic heart    │ No Match                                           │
│ failure at the target dose or maximum tolerance    │                                                    │
│ dose for over 1 month, or unchanged dose in last 1 │                                                    │
│ month                                              │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who plan to have cardiac transplantation  │ 8. Subjects who plan to have cardiac               │
│                                                    │ transplantation;                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Systolic blood pressure < 90mmHg                   │ 11. Systolic blood pressure < 90mmHg, or >         │
│                                                    │ 160mmHg;                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age: 18-75 years old                               │ 1. Age: 18-75 years old, no limitation in gender;  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Understand and sign the informed consent form      │ 6. Understand and sign the informed consent form;  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Claustrophobia                                     │ 4. Claustrophobia;                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject participated in any other clinical trial   │ 18. Subject participated in any other clinical     │
│ within the previous three months                   │ trial within the previous three months;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Chronic heart failure complicated with acute       │ 12. Chronic heart failure complicated with acute   │
│ hemodynamic disturbance or acute decompensation    │ hemodynamic disturbance or acute decompensation    │
│ within last 1 month                                │ within last 1 month;                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the past one month, the clinical condition      │ 4. In the past one month, the clinical condition   │
│ (including history, clinical symptoms and signs)   │ (including history, clinical symptoms and signs)   │
│ was relatively stable                              │ was relatively stable;                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Left ventricular ejection fraction (LVEF) ≤ 40%    │ 2. Left ventricular ejection fraction (LVEF) ≤ 40% │
│ (ECHO)                                             │ (ECHO);                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ subject with pre-cancerous disease manifested by   │ 19. Subject with previous history of tumor, or     │
│ pathological examination (such as ductal carcinoma │ current tumor patient, or subject with pre-        │
│ in situ or cervical epithelial dysplasia)          │ cancerous disease manifested by pathological       │
│                                                    │ examination (such as ductal carcinoma in situ or   │
│                                                    │ cervical epithelial dysplasia)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Severe hepatic and renal insufficiency (serum      │ 9. Severe hepatic and renal insufficiency (serum   │
│ creatinine>2.0 mg /dl, AST or ALT is five times    │ creatinine>2.0 mg /dl, AST or ALT is five times    │
│ higher than the upper limit of normal range)       │ higher than the upper limit of normal range);      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ current tumor patient                              │ 19. Subject with previous history of tumor, or     │
│                                                    │ current tumor patient, or subject with pre-        │
│                                                    │ cancerous disease manifested by pathological       │
│                                                    │ examination (such as ductal carcinoma in situ or   │
│                                                    │ cervical epithelial dysplasia)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Atrial fibrillation                                │ 1. Atrial fibrillation;                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject underwent cardiac pacemaker treatment      │ 2. Subject underwent cardiac pacemaker treatment;  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The Investigator deemed for whatever reason that   │ 21. The Investigator deemed for whatever reason    │
│ the subject is not likely to complete the study or │ that the subject is not likely to complete the     │
│ comply with the study procedures (due to           │ study or comply with the study procedures (due to  │
│ administration or any other reason)                │ administration or any other reason).               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject underwent metal graft treatment            │ 3. Subject underwent metal graft treatment;        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with chronic heart failure (NYHA class II │ 3. Patients with chronic heart failure (NYHA class │
│ or III)                                            │ II or III);                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject underwent cardiac surgery or               │ 7. Subject underwent cardiac surgery or            │
│ cerebrovascular events within the previous six     │ cerebrovascular events within the previous six     │
│ months                                             │ months;                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Acute myocardial infarction                        │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject with life expectancy less than 6 months as │ 17. Subject with life expectancy less than 6       │
│ assessed by investigators                          │ months as assessed by investigators;               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject with previous history of tumor             │ 19. Subject with previous history of tumor, or     │
│                                                    │ current tumor patient, or subject with pre-        │
│                                                    │ cancerous disease manifested by pathological       │
│                                                    │ examination (such as ductal carcinoma in situ or   │
│                                                    │ cervical epithelial dysplasia)                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ severe ventricular arrhythmia (polymorphic and     │ 13. Mobitz Type II or III° atrial ventricular      │
│ frequent premature ventricular beats, frequent     │ block，severe ventricular arrhythmia (polymorphic  │
│ non-sustained ventricular tachycardia)             │ and frequent premature ventricular beats, frequent │
│                                                    │ non-sustained ventricular tachycardia);            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ cardiac ischemia indicated by 6-minute walk test   │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ significant valve disease                          │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ constrictive pericarditis                          │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Systolic blood pressure > 160mmHg                  │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Examinations (physical examination, X-ray          │ 20. Examinations (physical examination, X-ray      │
│ examination, type-B ultrasonic detection or other  │ examination, type-B ultrasonic detection or other  │
│ methods) reveal that the subject has malignant     │ methods) reveal that the subject has malignant     │
│ mass, gland hyperplasia or adenoma with endocrine  │ mass, gland hyperplasia or adenoma with endocrine  │
│ activity, or impact on heart, or endocrine         │ activity, or impact on heart, or endocrine         │
│ function (such as pheochromocytoma, thyroid        │ function (such as pheochromocytoma, thyroid        │
│ enlargement)                                       │ enlargement);                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum potassium>5.5mmol/L                          │ No Match                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ hypertrophic cardiomyopathy                        │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ congenital heart disease                           │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ no limitation in gender                            │ 1. Age: 18-75 years old, no limitation in gender;  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Ischemic heart failure without the                 │ 6. Ischemic heart failure without the              │
│ revascularization or undergone the                 │ revascularization or undergone the                 │
│ revascularization within last 6 months             │ revascularization within last 6 months;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ severe pulmonary hypertension                      │ 5. Acute myocardial infarction, cardiac ischemia   │
│                                                    │ indicated by 6-minute walk test, hypertrophic      │
│                                                    │ cardiomyopathy, constrictive pericarditis,         │
│                                                    │ significant valve disease or congenital heart      │
│                                                    │ disease, severe pulmonary hypertension;            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum potassium<3.2mmol/L                          │ 14. Serum potassium<3.2mmol/L, or>5.5mmol/L;       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Childbearing-aged female subject who is unmarried  │ No Match                                           │
│ or does not bear child                             │                                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Mobitz Type II or III° atrial ventricular block    │ 13. Mobitz Type II or III° atrial ventricular      │
│                                                    │ block，severe ventricular arrhythmia (polymorphic  │
│                                                    │ and frequent premature ventricular beats, frequent │
│                                                    │ non-sustained ventricular tachycardia);            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female subject plan to become pregnant             │ No Match                                           │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛